Yamaguchi-Takegami N, Takahashi A, Mitsui J, Sugiyama Y, Chikada A, Porto K
Intern Med. 2023; 63(6):861-865.
PMID: 37558486
PMC: 11008993.
DOI: 10.2169/internalmedicine.1699-23.
Ormazabal M, Pavan E, Vaena E, Ferino D, Biasizzo J, Mucci J
Int J Mol Sci. 2023; 24(13).
PMID: 37446383
PMC: 10342917.
DOI: 10.3390/ijms241311204.
Chen D, Zheng Y, Zhang G, Huang Y, Zheng B, Zhang J
J Neural Transm (Vienna). 2023; 130(7):905-913.
PMID: 37280314
DOI: 10.1007/s00702-023-02651-4.
Moraitou M, Sotiroudis G, Papagiannakis N, Ferraz M, Xenakis A, Aerts J
PLoS One. 2023; 18(2):e0277602.
PMID: 36735655
PMC: 9897572.
DOI: 10.1371/journal.pone.0277602.
Angelopoulou E, Bougea A, Papageorgiou S, Villa C
Genes (Basel). 2022; 13(6).
PMID: 35741861
PMC: 9222985.
DOI: 10.3390/genes13061099.
Prevalence of Fabry Disease among Patients with Parkinson's Disease.
Lackova A, Beetz C, Oppermann S, Bauer P, Pavelekova P, Lorincova T
Parkinsons Dis. 2022; 2022:1014950.
PMID: 35111290
PMC: 8803460.
DOI: 10.1155/2022/1014950.
Gaucher disease - more than just a rare lipid storage disease.
Roh J, Subramanian S, Weinreb N, Kartha R
J Mol Med (Berl). 2022; 100(4):499-518.
PMID: 35066608
DOI: 10.1007/s00109-021-02174-z.
When Friendship Turns Sour: Effective Communication Between Mitochondria and Intracellular Organelles in Parkinson's Disease.
Lin T, Lin K, Lin K, Liou C, Chen S, Chuang Y
Front Cell Dev Biol. 2020; 8:607392.
PMID: 33330511
PMC: 7733999.
DOI: 10.3389/fcell.2020.607392.
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease.
Paciotti S, Albi E, Parnetti L, Beccari T
J Clin Med. 2020; 9(2).
PMID: 32098196
PMC: 7073989.
DOI: 10.3390/jcm9020594.
Fabry Disease With Concomitant Lewy Body Disease.
Del Tredici K, Ludolph A, Feldengut S, Jacob C, Reichmann H, Bohl J
J Neuropathol Exp Neurol. 2020; 79(4):378-392.
PMID: 32016321
PMC: 7092358.
DOI: 10.1093/jnen/nlz139.
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson P, Weinreb N, Cloyd J, Tuite P, Kartha R
Mol Genet Metab. 2019; 129(2):35-46.
PMID: 31761523
PMC: 7002237.
DOI: 10.1016/j.ymgme.2019.10.006.
The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin K, Lin K, Chen S, Liou C, Chuang Y, Lin H
Int J Mol Sci. 2019; 20(21).
PMID: 31731450
PMC: 6862467.
DOI: 10.3390/ijms20215312.
, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.
Riboldi G, Di Fonzo A
Cells. 2019; 8(4).
PMID: 31010158
PMC: 6523296.
DOI: 10.3390/cells8040364.
The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
Fog C, Zago P, Malini E, Solanko L, Peruzzo P, Bornaes C
EBioMedicine. 2018; 38:142-153.
PMID: 30497978
PMC: 6306395.
DOI: 10.1016/j.ebiom.2018.11.037.
The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.
Collins L, Williams-Gray C, Morris E, Deegan P, Cox T, Barker R
J Neurol. 2018; 265(8):1789-1794.
PMID: 29845374
PMC: 6060775.
DOI: 10.1007/s00415-018-8908-6.
Emptying the stores: lysosomal diseases and therapeutic strategies.
Platt F
Nat Rev Drug Discov. 2017; 17(2):133-150.
PMID: 29147032
DOI: 10.1038/nrd.2017.214.
The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D
Hum Mol Genet. 2016; 25(13):2712-2727.
PMID: 27162249
PMC: 6390410.
DOI: 10.1093/hmg/ddw129.
Glucocerebrosidase and parkinsonism: lessons to learn.
Markovic I, Kresojevic N, Kostic V
J Neurol. 2016; 263(5):1033-1044.
PMID: 26995357
DOI: 10.1007/s00415-016-8085-4.
The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A, Schapira A
J Neurochem. 2016; 139 Suppl 1:77-90.
PMID: 26860875
PMC: 5111601.
DOI: 10.1111/jnc.13385.
Mitochondrial dysfunction associated with glucocerebrosidase deficiency.
Gegg M, Schapira A
Neurobiol Dis. 2015; 90:43-50.
PMID: 26388395
PMC: 4838669.
DOI: 10.1016/j.nbd.2015.09.006.